624 related articles for article (PubMed ID: 9019154)
1. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
2. The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo.
Dhordain P; Albagli O; Ansieau S; Koken MH; Deweindt C; Quief S; Lantoine D; Leutz A; Kerckaert JP; Leprince D
Oncogene; 1995 Dec; 11(12):2689-97. PubMed ID: 8545127
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional repression by the proto-oncogene BCL-6.
Seyfert VL; Allman D; He Y; Staudt LM
Oncogene; 1996 Jun; 12(11):2331-42. PubMed ID: 8649773
[TBL] [Abstract][Full Text] [Related]
4. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene.
Davies JM; Hawe N; Kabarowski J; Huang QH; Zhu J; Brand NJ; Leprince D; Dhordain P; Cook M; Morriss-Kay G; Zelent A
Oncogene; 1999 Jan; 18(2):365-75. PubMed ID: 9927193
[TBL] [Abstract][Full Text] [Related]
5. Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression.
Albagli O; Dhordain P; Bernardin F; Quief S; Kerkaert JP; Leprince D
Biochem Biophys Res Commun; 1996 Mar; 220(3):911-5. PubMed ID: 8607866
[TBL] [Abstract][Full Text] [Related]
6. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
7. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
8. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation.
Bernardin F; Collyn-d'Hooghe M; Quief S; Bastard C; Leprince D; Kerckaert JP
Oncogene; 1997 Feb; 14(7):849-55. PubMed ID: 9047392
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of the LAZ3 (BCL6) proto-oncogene accompanies murine skeletal myogenesis.
Albagli-Curiel O; Dhordain P; Lantoine D; Auradé F; Quief S; Kerckaert JP; Montarras D; Pinset C
Differentiation; 1998 Nov; 64(1):33-44. PubMed ID: 9921651
[TBL] [Abstract][Full Text] [Related]
10. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci.
Albagli O; Lantoine D; Quief S; Quignon F; Englert C; Kerckaert JP; Montarras D; Pinset C; Lindon C
Oncogene; 1999 Sep; 18(36):5063-75. PubMed ID: 10490843
[TBL] [Abstract][Full Text] [Related]
11. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
12. Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger oncoprotein.
Li X; Peng H; Schultz DC; Lopez-Guisa JM; Rauscher FJ; Marmorstein R
Cancer Res; 1999 Oct; 59(20):5275-82. PubMed ID: 10537309
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of DPZF, a novel human BTB/POZ zinc finger protein sharing homology to BCL-6.
Zhang W; Mi J; Li N; Sui L; Wan T; Zhang J; Chen T; Cao X
Biochem Biophys Res Commun; 2001 Apr; 282(4):1067-73. PubMed ID: 11352661
[TBL] [Abstract][Full Text] [Related]
14. Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF.
Dhordain P; Albagli O; Honore N; Guidez F; Lantoine D; Schmid M; The HD; Zelent A; Koken MH
Oncogene; 2000 Dec; 19(54):6240-50. PubMed ID: 11175338
[TBL] [Abstract][Full Text] [Related]
15. BCL6 can repress transcription from the human immunodeficiency virus type I promoter/enhancer region.
Baron BW; Desai M; Baber LJ; Paras L; Zhang Q; Sadhu A; Duguay S; Nucifora G; McKeithan TW; Zeleznik-Le N
Genes Chromosomes Cancer; 1997 May; 19(1):14-21. PubMed ID: 9135990
[TBL] [Abstract][Full Text] [Related]
16. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
17. The t(2;3)(q21;q27) translocation in non-Hodgkin's lymphoma displays BCL6 mutations in the 5' regulatory region and chromosomal breakpoints distant from the gene.
Chen W; Butler M; Rao PH; Chaganti SR; Louie DC; Dalla-Favera R; Chaganti RS
Oncogene; 1998 Oct; 17(13):1717-22. PubMed ID: 9796700
[TBL] [Abstract][Full Text] [Related]
18. Recognition DNA sequence of a novel putative transcription factor, BCL6.
Kawamata N; Miki T; Ohashi K; Suzuki K; Fukuda T; Hirosawa S; Aoki N
Biochem Biophys Res Commun; 1994 Oct; 204(1):366-74. PubMed ID: 7945383
[TBL] [Abstract][Full Text] [Related]
19. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene.
Kikuchi M; Miki T; Kumagai T; Fukuda T; Kamiyama R; Miyasaka N; Hirosawa S
Oncogene; 2000 Oct; 19(42):4941-5. PubMed ID: 11039912
[TBL] [Abstract][Full Text] [Related]
20. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
